Clinical Trial Update: A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET

View source ↗

Summary

A prospective, multicenter evaluation of Fluciclovine F-18 PET imaging in men with biochemical recurrence of prostate cancer after negative or inconclusive PSMA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Axumin (fluciclovine F-18)

Snippet

Sponsor: Technical University of Munich | Conditions: Biochemical Recurrence of Malignant Neoplasm of Prostate | Status: RECRUITING